After revenue jumps 60%, is Oxford Biodynamics plc a buy?

Could Oxford Biodynamics PLC (LON: OBD) be London’s next super growth stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are many early-stage biotech companies trading on AIM today that don’t deserve a second glance. Most of these highly speculative companies will never reach the production stage and will certainly never reach profitability.

Already revenue-generating

Oxford Biodynamics (LSE: OBD) does not fall into this category. Shares in Oxford first started trading on AIM at the beginning of December last year, after the company was spun-out of the University of Oxford. The company is focused on epigenetics and its technology analyses biomarkers in the blood to help pharma companies work out which patients are likely to benefit most from a particular drug. 

Oxford raised £20m through the public offering, of which £7.1m found its way to the company’s coffers, giving it working capital for the next two to three years. The cash will help the group expand its offering and break into the US market. 

Unlike other early stage biotechs, Oxford is already revenue-generating, getting its income through contracts with pharmaceutical groups. And today’s results from the group show that revenue jumped nearly 60% last year from £0.7m to £1.1m. 

Unfortunately, the group is still loss making and reported an operating loss of £2.3m for the year. After adjusting for one-off IPO costs the operating losses amounted to £1.9m, up from a loss of £1.6m the year before. 

Exciting year ahead 

After a transformational 2016, 2017 is expected to be a year of growth for Oxford. As the company looks to expand its offering, pre-tax losses are expected to rise to £4.1m for the next fiscal year,but this should lead to growth. Analysts have pencilled in revenue of £3.1m for the fiscal year ending 30 September 2018 and a pre-tax loss of £1.7m, around 60% better than the year before. 

As with all early stage biotechs, Oxford is a high-risk/high-reward investment. The company may see sales and profits explode over the next few years but it may also struggle to build the customer base required to achieve escape velocity.

Nonetheless, it seems there is demand for the company’s offering. The group recently signed a pilot development agreement with Singapore-based EpiFit, to analyse the effect of EpiFit’s fitness regimes. If successful the agreement could translate into a multi-year contract but as of yet nothing is certain. 

Still, Oxford has several years of working capital in the bank after its recent IPO, giving the group plenty of headroom to get the business up and running. 

A safer buy? 

As a small-cap company Oxford is a speculative investment — but so, to some extent, is the company’s much larger sector peer AstraZeneca (LSE: AZN).

2017 promises to be a make or break year for Astra as the company awaits the results of major clinical trials this year. The biggest one, called ‘Mystic’, involves two ground-breaking lung cancer drugs. If these tests prove that the treatments are effective, they could produce more than $6bn per annum for Astra when they enter production. 

Astra is expected to report a 6% slump in revenue and a 7% fall in profits for 2016, so the group needs some positive test results to reassure investors about its outlook. 

The bottom line 

After reporting a 60% increase in revenue Oxford Biodynamics may be a ‘buy’, but the company is a highly specualtive bet. For the risk adverse investor, Astra might be a more sensible purchase. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£8 per year in extra income for life, for each £100 invested today? Here’s how!

Christopher Ruane explains how he would aim to set up extra income streams for the rest of his life by…

Read more »

Photo of a man going through financial problems
Investing Articles

With a £20K Stocks and Shares ISA, I’d target £1,964 in annual dividends like this

With an annual passive income target close to £2,000, our writer explains how he'd put a £20K Stocks and Shares…

Read more »

Illustration of flames over a black background
Investing Articles

Down 63% in 2024, what’s going on with the Avacta (AVCT) share price?

2024 has been a difficult year for many companies in the biotechnology sector, with the AVCT share price down heavily.…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Here’s how I’d invest £800 the Warren Buffett way!

Christopher Ruane learns some lessons from super-investor Warren Buffett he hopes could improve his own stock market performance.

Read more »

British Isles on nautical map
Investing Articles

Michael Burry just bought 175,000 shares in this FTSE 100 company

Scion Asset Management announced a $6.5bn stake in BP this week. But what could Michael Burry be seeing in an…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

£5,000 in savings? Here’s how I’d aim to start making powerful passive income today

With a cash lump sum to invest, this Fool lays out how he'd start making passive income. He also details…

Read more »

Investing Articles

Just released: our 3 top small-cap stocks to consider buying before June [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

My best FTSE 250 stock to consider buying now for passive income while it’s near 168p

This is a rare stock with a growing underlying business and a fat dividend yield – it’s worth consideration for…

Read more »